CSL787 / CSL Behring, HCmed - LARVOL DELTA

Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB) (clinicaltrials.gov) - P2 | N=450 | Recruiting | Sponsor: CSL Behring | Not yet recruiting ➔ Recruiting

Enrollment open • Bronchiectasis • Genetic Disorders • Immunology • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases

Safety and efficacy of CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: Phase 1 results and Phase 2b trial design (WBC 2025) - "Error! Bookmark not defined."

Clinical • P1 data • P2b data • Bronchiectasis • Pulmonary Disease • Respiratory Diseases

Safety and efficacy of CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: Phase 1 results and Phase 2b trial design (WBC 2025) - No abstract available

Clinical • Late-breaking abstract • P1 data • P2b data • Bronchiectasis • Pulmonary Disease • Respiratory Diseases

Late Breaking Abstract - CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: a Phase 1 trial (ERS 2025) - "CSL787 showed a favourable safety profile with no serious TEAEs. There were notable reductions in sputum bacterial counts. These findings support further evaluation of CSL787."

Clinical • Late-breaking abstract • P1 data • Bronchiectasis • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB) (clinicaltrials.gov) - P2 | N=450 | Not yet recruiting | Sponsor: CSL Behring

New P2 trial • Bronchiectasis • Genetic Disorders • Immunology • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases

Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB) (clinicaltrials.gov) - P1 | N=64 | Completed | Sponsor: CSL Behring | Recruiting ➔ Completed

Trial completion • Bronchiectasis • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases

Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB) (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: CSL Behring | Trial completion date: Nov 2022 ➔ Jun 2023 | Trial primary completion date: Nov 2022 ➔ Jun 2023

Trial completion date • Trial primary completion date • Bronchiectasis • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases

Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB) (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: CSL Behring | Trial completion date: May 2022 ➔ Nov 2022 | Trial primary completion date: May 2022 ➔ Nov 2022

Trial completion date • Trial primary completion date • Bronchiectasis • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases

Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB) (clinicaltrials.gov) - P1; N=64; Recruiting; Sponsor: CSL Behring; Trial completion date: Dec 2021 ➔ Apr 2022; Trial primary completion date: Dec 2021 ➔ Apr 2022

Clinical • Trial completion date • Trial primary completion date • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases

HCmed Signs a Global Development Agreement with Global Biotechnology Leader CSL Behring (PRNewswire) - "HCmed today announces the start of a strategic partnership with global biotherapeutics leader CSL Behring to collaboratively develop CSL Behring's plasma derived immunoglobulin administered via HCmed's new generation vibrating-mesh nebulizing device (CSL787). Under the terms of the agreement, CSL Behring will have sole responsibility for the development and commercialization of the combination product, with HCmed leading the development of the customized nebulizing device specifically optimized for CSL Behring's formulation."

Licensing / partnership • Non‐Cystic Fibrosis Bronchiectasis

Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB) (clinicaltrials.gov) - P1; N=64; Recruiting; Sponsor: CSL Behring; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Non‐Cystic Fibrosis Bronchiectasis • Respiratory Diseases

Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB) (clinicaltrials.gov) - P1; N=64; Not yet recruiting; Sponsor: CSL Behring

Clinical • New P1 trial • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Non‐Cystic Fibrosis Bronchiectasis • Respiratory Diseases